Teva Pharmaceutical Industries Ltd (Petach Tikva, Israel) signed a definitive agreement with Allergan plc (Dublin, Ireland) to acquire Allergan Generics in a transaction valued at $40.5 billion. Allergan will receive $33.75 billion in cash and shares of Teva valued at approximately $6.75 billion, representing an estimated under 10 percent ownership stake in Teva. The transaction was unanimously approved by the boards of directors of both companies and is expected to close in Q1 2016.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.